| INTRODUC TI ON
Malignant tumours are the most threatening human diseases around the world. In 2018, there were about 18.1 million new cancer cases and 9.6 million cancer-related deaths. 1 Among them, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death among women. The incidence of this aggressive disease remains alarmingly high with more than one million newly diagnosed cases each year. [1] [2] [3] Understanding the molecular mechanisms of breast carcinogenesis is an important task for researchers to develop new methods for diagnosis and treatment of this malignancy. Despite years of research, the overall 5-year survival rate for patients with breast cancer remains low. 4, 5 Therefore, there is still an urgent need for finding reliable biomarkers for early diagnosis, accurate prognosis and targeted therapy. 6 F I G U R E 1 PKMYT1 mRNA expression was elevated in human breast cancer. A, This graph generated by Oncomine indicates the numbers of datasets with statistically significant mRNA overexpression (red) or downexpression (blue) of PKMYT1, WEE1 and WEE1B (cancer tissues vs corresponding normal tissues). The threshold was defined with the following parameters: P-value of 1E-4, fold change of 2 and gene ranking of 10%. B, C, The GEPIA database verified that PKMYT1 gene expression was significantly upregulated in breast cancer tissues (BRCA) (n = 1085) compared with normal breast tissues (n = 291), *P < .05 During cell cycle, normal cells maintain the stability of the genome primarily through the DNA damage checkpoints, a surveillance mechanism that is frequently deregulated in cancers.
Because of the loss-of-function of tumour suppressor genes, such as mutations in p53 that leads to the inactivation of the G1 checkpoint, many cancerous cells heavily rely on G2/M checkpoint to ensure its genomic stability and survival advantage. The WEE kinase, consisting of three family members in human, including PKMYT1
(membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase) and two WEE1 kinases (WEE1 and WEE1B), is protein kinase that activate the G2/M checkpoint of the cell cycle in response to double-stranded DNA breaks. 7, 8 Early study has
shown that WEE1 inhibitors are effective against TP53-mutant cancer cells, which account for over 80% of triple-negative breast cancer (TNBC) cases. 9
PKMYT1 is essential for Golgi and endoplasmic reticulum assembly in mammalian cells. It has been shown to be involved in G2 arrest in oocytes and its activity is regulated by AKT phosphor- inhibitor renders apoptosis in TNBC cells, but its clinical application remains limited. 9, 14, 15 In other aspect, the role of PKMYT1 in breast cancer development remains unknown and awaits further investigations. In this work, we applied a wide range of integrated bioinformatics approach to assess the importance of PKMYT1 by analysing the expression, potential function and prognostic impact of PKMYT1 in human breast cancer.
| MATERIAL S AND ME THODS

| Data mining in Oncomine database
The Oncomine database (https ://www.oncom ine.org/resou rce/ login.html) is a publicly accessible, online cancer microarray database that helps facilitate research from genome-wide expression analysis. We used the Oncomine database to determine the transcription level of the PKMYT1 gene in breast cancer 16, 17 by retrieving expression levels of PKMYT1 mRNA (log2-transformed)
in breast cancer vs normal tissues for statistical comparison. To obtain the most important PKMYT1 probe, the thresholds were set as follows: P-value < 1E-4, fold change >2 and the gene ranks in the top 10%.
| University of California Santa Cruz (UCSC) cancer genomics browser analysis
The UCSC Cancer Genomics Browser (http://xena.ucsc.edu/) 18, 19 was used to verify the heat map of PKMYT1 expression, and the correlation between PKMYT1 and hub genes expression were analysed.
| Catalogue of somatic mutations in cancer (COSMIC) analysis for PKMYT1 mutations
The COSMIC database (http://cancer.sanger.ac.uk) is a high-resolution resource for studying the effects of somatic mutations in all forms of human tumours. We used this database to analyse mutations in PKMYT1 in breast cancer. 20, 21 An overview of the distribution and substitutions on the coding strand in breast cancer was depicted in a pie chart.
| Breast Cancer Gene-Expression Miner v4.0 (bc-GenExMiner v4.0)
The expression of PKMYT1 and its prognostic value in breast cancer were evaluated using Breast Cancer Gene-Expression Miner v4.0 online dataset (http://bcgen ex.centr egaud ucheau.fr), which is a statistical mining tool that contains published annotated genomic data, including 36 annotated genomic datasets and 5861 patients with breast cancer. 22, 23 Correlation between PKMYT1 and PLK1 genes was estimated by Pearson's correlation module of bc-GenExMiner v4.0. 
| cBioPortal database analysis
| Gene correlation analysis in GEPIA
The online database Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/index.html) 26 is an interactive web that includes 9736 tumours and 8587 normal samples from 
RFS luminal A
Number of samples(%) Nonsense substitution 3(33.33%) Missense substitution 5(55.56%) Synonymous substitution 0(0.00%) Inframe insertion 0 (0.00%) Frameshift insertion 0 (0.00%) Inframe deletion 1 (11.11%) Frameshift deletion 0(0.00%) Complex mutation 0(0.00%) Other 0(0.00%) Total unique samples 9
Colour Mutation type Number of samples(%) were as follows: MCODE score > 5 points, degree cut-off = 2, node score cut-off = 0.2, Max depth = 100, and k-Score = 2.
| Functional and KEGG Pathway Enrichment Analysis
DAVID (http://david.abcc.ncifc rf.gov/) is a functional annotation tool that reveals the biological significance behind by entering a list of genes. 29, 30 Based on the extracted co-expressed genes, GO analysis can be divided into three categories: biological processes (BP), cellular components (CC) and molecular functions (MF). 31 The KEGG pathway database is used to identify biological pathways for co-expressed gene enrichment. 32 Statistical significance was assessed using Fisher's exact test, and P-value < .05 was considered significant.
| Statistical analysis
All statistical analyses were performed by default as described by 
| RE SULTS
| Up-regulation of PKMYT1 mRNA expression in human breast cancer
We analysed the expression profile of WEE family kinases using 
| PKMYT1 mutations are rare and high PKMYT1 expression predicts poor prognosis in breast cancer
We employed cBioPortal to evaluate the frequency of changes in PKMYT1 mutations in breast cancer. The frequency of mutation is very low, only 0.1% ( Figure 3A) . The mutations of PKMYT1 in breast cancer were analysed using the COSMIC database. The pie chart describes the types of mutations, including nonsense mutations, missense mutations, and in-frame deletions, the largest proportion of which are missense mutations, up to 55.56% ( Figure 3B ). 
F I G U R E 4 Associations between PKMYT1 gene expressions and clinical
| The associations of PKMYT1 expression profiles and clinical parameters in breast cancer patients
The expression profiles of PKMYT1 were examined across PAM50 breast cancer subtypes using 5861 patients with breast cancer cohorts in bc-GenExMiner 4.0, based on different clinical-pathological indicators; estrogen receptors group and progesterone receptors groups were compared with the corresponding positive groups. PKMYT1 mRNA expression was significantly increased in the body of ER-and PR-groups, (P < .0001), (Table 2 and Figure 4A ,B). However, compared with HER2+, HER2-patients had somewhat decrease in PKMYT1 mRNA levels with P-value of 0.0118 ( Figure 4C ). In addition, patients with Basal-like status showed significantly increased PKMYT1 expression (P < .0001) compared with patients with negative Basal-like status ( Table 2 and Figure 4D ). Compared with non-TNBC group, PKMYT1 mRNA expression was significantly higher in TNBC patients (P < .0001) ( Table 2 and Figure 4E ), but not in the case with Nodal Status (P = .8173) ( Table 2 and Figure 4F ). In the Scarff, Bloom and Richardson (SBR) grade 34 status criteria, increased SBR levels were significantly associated with increased PKMYT1 transcript levels in relative to the SBR1 group (P < .0001) ( Figure 4G ).
There was no significant relationship between ages (P = .3099) ( Figure 4H ). With higher rate of Nottingham Prognostic Index (NPI) classification, the lower of the survival rate was associated ( Figure 4I ).
| KEGG and GO enrichment analysis revealing functional association of PKMYT1 with cell proliferation
The Oncomine database (Stickeler Breast dataset) ( Figure 5A (Table 3) . Collectively, these data suggest an essential role of PKMYT1 in regulating cell proliferation in breast cancer. 
| PKMYT1 PPI network construction and analysis of 10 hub genes
Using the STRING database, the co-expressed 80 genes were constructed into a protein-protein network, and the most important module was obtained using Cytoscape (MCODE plug-in) ( Figure 6A) . The top ten genes, including PLK1, NCAPH, TRIP13, KIF4A, SPAG5, CDCA5, FOXM1, ESPL1, PRC1 and CENPN, were identified as potential hub genes according to the degree score generated by CytoHubba plug-in (the cytoHubba plug-in, top 10 nodes ranked by DMNC) ( Figure 6B ), consistent with their enrichment in the top module analysed by MCODE (highlighted in yellow) ( Figure 6A ). The biological process analysis of hub genes was further performed using BINGO plug-in. Particularly, peptide biosynthetic process, phytochelatin biosynthetic process, cellular biosynthetic process, peptide metabolic process, secondary metabolic process and phytochelatin metabolic process were largely altered, suggesting that they may participate in the protein anabolism required for cell division ( Figure 6C ). Hierarchical clustering of the hub genes was performed using UCSC Cancer Genomics Browser ( Figure 6D ), indicating the concordant expression pattern across 10 genes. Furthermore, the overall survival of hub genes was analysed using Kaplan-Meier curve. All these 10 hub genes exhibited poorer overall survival rate in higher expression groups ( Figure 6E ).
Amongst these hub genes, PLK1 may be the most attractive target in cell proliferation. A large number of studies have shown that PLK1 is one of the serine-threonine kinase families highly expressed in prostate cancer, 35 neuroblastoma cells, 36 acute myeloid leukaemia, 37 cervical cancer 38 and other malignant tumours, which plays an important role in the initiation, maintenance and completion of mitosis. Interestingly, PLK1 has been proposed to be the functional partner of PKMYT1 in regulating cell cycle, 7, 39, 40 and PLK1 is also closely related to breast cancer, 41 implying that PLK1 and PKMYT1 may play an cooperative role in the development of breast cancer.
| Co-expression of PKMYT1 and PLK1
cBioportal regression analysis showed that PKMYT1 and PLK1 had high correlation coefficients (Spearman's correlation = 0.79;
Pearson's correlation = 0.60) ( Figure 7A ). This positive correlation between PKMYT1 and PLK1 transcript was substantiated by the analysis via both the bc-GenExMiner 4.0 database ( Figure 7B ) and GEPIA ( Figure 7C ). This was further confirmed using UCSC Xena with consistent correlative patterns in different subtypes ( Figure 7D ). These data demonstrate that PKMYT1 has a strong association with PLK1, suggesting that they may be functional partners in breast carcinoma.
| High PLK1 expression predicts unfavourable prognosis in patients with breast cancer
To determine the genetic alteration of PLK1 in breast cancer, the expression profile of PLK1 was investigated using the Oncomine Figure 8A ). Subsequently, the prognostic value of PLK1 in breast cancer was studied by Kaplan-Meier plotter database, and it was confirmed that high expression of PLK1 mRNA was significantly associated with the decrease of RFS, OS, DMFS and PPS in breast cancer ( Figure 8B ). to the lack of therapeutic targets, patients with TNBC are unable to benefit from endocrine therapy or HER2-targeted therapy, which is the current mainstay of adjuvant therapy. Furthermore, patients with TNBC are more likely to develop chemoresistance. As shown by our study, high expression of PKMYT1 largely predicts the unfavourable prognosis in TBNC with shorter period of RFS. Thus, targeting PKMYT1 may be a promising strategy for therapeutic intervention against TNBC.
F I G U R E 8
Previous study has suggested a potential link between PKMYT1
and β-catenin/TCF signalling as shown by downregulation of β-catenin signalling via PKMYT1 depletion in human derived hepatoma HuH-6 cells. 44 β-catenin/TCF signalling is known to be a driving force of EMT in various cancers. 46 Several major EMT modulators (twist, snail, slug, etc) are target genes for β-catenin/TCF signalling. 47, 48 Given that EMT is a key limiting step in metastasis, 49 targeting β-catenin/TCF signalling via PLMYT1 inhibition may be a promising strategy for cancer therapy.
Polo-like kinase (PLK1), a key regulatory kinase involved in mitosis and cell cycle progression, 50, 51 plays an important role in tumour cell anabolism by activating the pentose phosphate pathway. 52 The positive correlation of PLK1 and PKMYT1 in cancer cells may indicate a particular G2 checkpoint mechanism which synchronizes the rapid cell proliferation in accordance with maintenance of genomic stability. Mechanistically, PKMYT1 is highly expressed in cancer cells, and G2/M check is performed to ensure genomic stability. Simultaneously, the duration for G2/M checkpoint should be precisely controlled by PLK1 regulatory pathway for rapid cell proliferation. Co-targeting these two collaborative kinases might be an efficient way to treat breast carcinoma.
In summary, we have confirmed the up-regulation of PKMYT1 and its partner, PLK1, in breast cancer and validated their importance as prognostic factors. We propose that PKMYT1 could be a promising molecular target for the diagnosis and treatment of breast cancer.
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